Landfar Bio medicine Co (000504.SZ) Osake Kurssi

Landfar Bio medicine Co Ltd, listed on the Shenzhen Stock Exchange under ticker 000504.SZ, operates as a biotechnology company based in Changsha, China. The company went public on December 8, 1992, and currently employs 512 people. Its primary business activities include the manufacture and sale of pharmaceutical products, with a focus on biomedical services such as stem cell storage, technical services, and research into stem cell treatments. Additionally, the company engages in medical instrument purchasing and sales. Landfar Bio medicine also operates within the energy conservation and environmental protection sector, offering services like contract energy management through energy management companies (EMCs), build-transfer (BT) projects, product sales, and sewage treatment solutions. The firm primarily serves the domestic Chinese market, with no indication of significant international operations. Its official website is http://www.nhbiogroup.com/, though the source description provided contains conflicting information referring to the company as NanHua Bio-medicine Co., Ltd., which may be an error or an alternate name. The company’s industry classification is biotechnology within the healthcare sector, reflecting its focus on innovative medical solutions and environmental sustainability initiatives. Landfar Bio medicine Co Ltd maintains a presence in Changsha, Hunan, and its operations are centered around pharmaceuticals, biomedical services, and environmental technologies.